Biocon secures 10 year pertuzumab supply partnership for Brazil’s public healthcare system

Biocon has entered into a partnership with Bahiafarma and Bionovis for pertuzumab in Brazil, securing access to the country’s public healthcare market through a 10 year Productive Development Partnership programme.

The consortium has been awarded 100% of the allocation for pertuzumab under Brazil’s PDP framework. The agreement gives the partners exclusive access to the public healthcare sector, which represents around 70% of national demand for the HER2 positive breast cancer therapy.

Biocon said the arrangement is expected to support wider and more sustained use of its pertuzumab product across Brazil’s public oncology system.

Under the terms of the programme, Biocon will receive milestone payments alongside a share of revenue generated from the Brazilian PDP opportunity over the 10 year period.

The agreement also includes plans for the product to be progressively localised in Brazil over the medium to long term as part of the PDP model.

Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon, said Brazil remains an important market for the company and highlighted the role of partnerships in strengthening local capabilities while improving access to affordable medicines.

He said the long term pertuzumab supply agreement represents an important step in expanding access for people with HER2 positive breast cancer. Tambe added that the collaboration combines Biocon’s scientific and manufacturing capabilities with the local expertise of Bahiafarma and Bionovis to support a more sustainable supply pathway for the therapy.

Ceuci Nunes, Chief Executive Officer of Bahiafarma, said the agreement represents progress in a strategically important public health project. She added that the collaboration could help Brazil increase its ability to produce essential medicines for the Unified Health System through the transfer and incorporation of advanced technology.

Odnir Finotti, Chief Executive Officer of Bionovis, said the partnership supports Brazilian public health and industrial policies while improving access to complex biological medicines. He also highlighted the potential for the project to strengthen local manufacturing, create specialist employment and increase national production capacity.

Pertuzumab is a monoclonal antibody used to treat HER2 positive breast cancer.

The medicine is not currently manufactured domestically in Brazil and represents a significant cost for the country’s Unified Health System.

Bahiafarma is a public pharmaceutical laboratory operated by the State of Bahia and focuses on pharmaceutical research, technological development, innovation and the manufacture and supply of medicines and other healthcare products, particularly for Brazil’s public health system.

Bionovis is a Brazilian biotechnology company specialising in the development, manufacture and commercialisation of complex biological medicines and biosimilars. Its activities include technology transfer, domestic biopharmaceutical production and efforts to broaden access to advanced therapies.

---

---

Related Topics and Keywords

Biocon, biosimilar, biotech, Brazil, breast cancer, Cancer, Oncology, pertuzumab, pharma news